Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in Preoperative Recurrent Glioblastoma
NCT02133183Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2014
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sapanisertib in glioblastoma (GBM) and Gliosarcoma (GS) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Proportion of patients who achieve a drug concentration >= 70 nM in contrast enhancing tumor tissue up to 2 years, Difference in ratio of the S6 phosphorylation over the total between the two groups up to 2 years and 1 more. Started Jul 2014; status: terminated.
02
Drugs
sapanisertib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02133183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133183.